SCHEMBL3563236

SCHEMBL3563236

CC(=O)c1csc(-n2ccnc2)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.47
CYP3A4 P08684 1/20 0.46
BAZ2B Q9UIF8 1/20 0.46
KDM1A O60341 4/20 0.39
HTT P42858 1/20 0.37
CD38 P28907 4/20 0.36
IDO1 P14902 1/20 0.36
ADH5 P11766 1/20 0.35
MAPT P10636 2/20 0.35
ENPP2 Q13822 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
LDHA P00338 1/20 0.34
LMNA P02545 1/20 0.34
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31216537 0.86 CHEK1 (0.48) CHEK1ADH5LDHA
SCHEMBL31216581 0.84 HTT (0.50) CHEK1CYP3A4BAZ2BHTTCD38
SCHEMBL5868906 0.80 RAB9A (0.51) CHEK1MAPTNPC1RAB9ALMNA
SCHEMBL3561692 0.79 CHEK1 (0.42) CHEK1CYP3A4BAZ2BHTTCD38
SCHEMBL3561688 0.77 CHEK1 (0.48) CHEK1CYP3A4HTTCD38MAPT
SCHEMBL21912296 0.76 ALDH1A1 (0.45) CHEK1HTTCD38MAPTNPC1
SCHEMBL5868797 0.76 CHEK1 (0.44) CHEK1CYP3A4BAZ2BHTTCD38
SCHEMBL9925916 0.75 L3MBTL1 (0.39) CHEK1CYP3A4MAPTENPP2MKNK1
SCHEMBL18708314 0.71 CHEK1 (0.39) CHEK1CYP3A4CD38IDO1MAPT
SCHEMBL12402348 0.71 CYP3A4 (0.37) CHEK1CYP3A4IDO1MAPTENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 CHEK1 4415/4885CYP3A4 80/4885BAZ2B 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.